Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Exjade in AML and High Risk MDS
NCT02233504Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Aug 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deferasirox in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 2 years. Started Aug 2014; status: completed.
02
Drugs
deferasirox
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02233504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02233504.